Top

Published in:

Open Access 01-12-2016 | Original Article

Downregulation of ARHGDIA contributes to human glioma progression through activation of Rho GTPase signaling pathway

Authors: Weiliang Lu, Xixi Wang, Jingjing Liu, Yu He, Ziwei Liang, Zijing Xia, Ying Cai, Liangxue Zhou, Hongxia Zhu, Shufang Liang

Published in: Tumor Biology | Issue 12/2016

Abstract

The protein ARHGDIA has been found to play distinct roles in cancer progression for several tumors. However, it remains elusive whether and how ARHGDIA plays functions in human glioma. In this study, we discovered that ARHGDIA is much downregulated in human glioma; meanwhile, its expression negatively correlates with glioma malignancy and positively relates to prognosis of glioma patients. It has independent predictive value of ARHGDIA expression level for overall survival of human glioma patients. Glioma patients with ARHGDIA-positive expression have a longer overall survival time than ARHGDIA-negative patients. Knockdown of ARHGDIA promotes cell proliferation, cell cycle progression, and cell migration due to the activation of Rho GTPases (Rac1, Cdc42, and RhoA) and Akt phosphorylation, whereas overexpression of ARHGDIA suppresses cell growth, cell cycle progression, and cell migration. ARHGDIA is a potential prognostic marker and therapeutic target for human glioma.

Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. Cbtrus statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology. 2013;15 Suppl 2:ii1–56.CrossRefPubMedPubMedCentral

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 who classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRefPubMedPubMedCentral

Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.CrossRefPubMed

Liang S, Shen G. Biomarkers of glioma. INTECH Open Access Publisher, 2011.

Cherfils J, Zeghouf M. Regulation of small gtpases by gefs, gaps, and gdis. Physiol Rev. 2013;93:269–309.CrossRefPubMed

Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K, et al. Prognostic value of rho gtpases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res. 2003;9:6432–40.PubMed

Liang L, Li Q, Huang L, Li D, Wang Y, Li X, et al. Loss of arhgdia expression is associated with poor prognosis in hcc and promotes invasion and metastasis of hcc cells. Int J Oncol. 2014.

Harding MA, Theodorescu D. Rhogdi signaling provides targets for cancer therapy. Eur J Cancer. 2010;46:1252–9.CrossRefPubMed

Hoffman GR, Nassar N, Cerione RA. Structure of the rho family gtp-binding protein cdc42 in complex with the multifunctional regulator rhogdi. Cell. 2000;100:345–56.CrossRefPubMed

10.

Liang S, Xu Y, Shen G, Zhao X, Zhou J, Li X, et al. Gene expression and methylation status of 14-3-3σ in human renal carcinoma tissues. IUBMB Life. 2008;60:534–40.CrossRefPubMed

11.

Jin X, Liu Y, Liu J, Lu W, Liang Z, Zhang D, et al. The overexpression of iqgap1 and β-catenin is associated with tumor progression in hepatocellular carcinoma in vitro and in vivo. PLoS One. 2015;10:e0133770.CrossRefPubMedPubMedCentral

12.

Zhang LH, Yin AA, Cheng JX, Huang HY, Li XM, Zhang YQ, et al. Trim24 promotes glioma progression and enhances chemoresistance through activation of the pi3k/akt signaling pathway. Oncogene. 2014;34:600–10.CrossRefPubMed

13.

Boulter E, Garcia-Mata R, Guilluy C, Dubash A, Rossi G, Brennwald PJ, et al. Regulation of rho gtpase crosstalk, degradation and activity by rhogdi1. Nat Cell Biol. 2010;12:477–83.CrossRefPubMedPubMedCentral

14.

Ponomarev I, Wang S, Zhang L, Harris RA, Mayfield RD. Gene coexpression networks in human brain identify epigenetic modifications in alcohol dependence. J Neurosci. 2012;32:1884–97.CrossRefPubMedPubMedCentral

15.

Zugasti O, Rul W, Roux P, Peyssonnaux C, Eychene A, Franke TF, et al. Raf-mek-erk cascade in anoikis is controlled by rac1 and cdc42 via akt. Mol Cell Biol. 2001;21:6706–17.CrossRefPubMedPubMedCentral

16.

Goldberg L, Kloog Y. A ras inhibitor tilts the balance between rac and rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res. 2006;66:11709–17.CrossRefPubMed

17.

Zhao L, Wang H, Sun X, Ding Y. Comparative proteomic analysis identifies proteins associated with the development and progression of colorectal carcinoma. FEBS J. 2010;277:4195–204.CrossRefPubMed

18.

Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics. 2002;2:76–84.CrossRefPubMed

19.

Reyes SB, Narayanan AS, Lee HS, Tchaicha JH, Aldape KD, Lang FF, et al. Alphavbeta8 integrin interacts with rhogdi1 to regulate rac1 and cdc42 activation and drive glioblastoma cell invasion. Mol Biol Cell. 2013;24:474–82.CrossRefPubMedPubMedCentral

20.

Lee HS, Cheerathodi M, Chaki SP, Reyes SB, Zheng Y, Lu Z, et al. Protein tyrosine phosphatase-pest and beta8 integrin regulate spatiotemporal patterns of rhogdi1 activation in migrating cells. Mol Cell Biol. 2015;35:1401–13.CrossRefPubMedPubMedCentral

21.

Forget M-A, Desrosiers RR, Del Maestro RF, Moumdjian R, Shedid D, Berthelet F, et al. The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin Exp Metastasis. 2002;19:9–15.CrossRefPubMed

22.

Turner SJ, Zhuang S, Zhang T, Boss GR, Pilz RB. Effects of lovastatin on rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem Pharmacol. 2008;75:405–13.CrossRefPubMed

23.

Wei L, Imanaka-Yoshida K, Wang L, Zhan S, Schneider MD, DeMayo FJ, et al. Inhibition of rho family gtpases by rho gdp dissociation inhibitor disrupts cardiac morphogenesis and inhibits cardiomyocyte proliferation. Development. 2002;129:1705–14.PubMed

24.

Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by rac1 gtpase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370–6.CrossRefPubMed

Title: Downregulation of ARHGDIA contributes to human glioma progression through activation of Rho GTPase signaling pathway
Authors: Weiliang Lu
Xixi Wang
Jingjing Liu
Yu He
Ziwei Liang
Zijing Xia
Ying Cai
Liangxue Zhou
Hongxia Zhu
Shufang Liang
Publication date: 01-12-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 12/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5374-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2016

Retraction Note to: Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology

Integrated analysis identified an intestinal-like and a diffuse-like gene sets that predict gastric cancer outcome

LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes

An indispensable role of CPT-1a to survive cancer cells during energy stress through rewiring cancer metabolism

Regulation of autophagy by Ca2+

VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin

Keynote webinar | Spotlight on antibody–drug conjugates in cancer